Annual CFO
$345.58 M
+$280.48 M+430.84%
31 December 2023
Summary:
Amneal Pharmaceuticals annual cash flow from operations is currently $345.58 million, with the most recent change of +$280.48 million (+430.84%) on 31 December 2023. During the last 3 years, it has fallen by -$33.42 million (-8.82%). AMRX annual CFO is now -8.82% below its all-time high of $379.00 million, reached on 31 December 2020.AMRX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
$141.77 M
+$102.12 M+257.50%
30 September 2024
Summary:
Amneal Pharmaceuticals quarterly cash flow from operations is currently $141.77 million, with the most recent change of +$102.12 million (+257.50%) on 30 September 2024. Over the past year, it has increased by +$60.39 million (+74.20%). AMRX quarterly CFO is now -45.40% below its all-time high of $259.65 million, reached on 31 December 2018.AMRX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
$312.84 M
+$60.39 M+23.92%
30 September 2024
Summary:
Amneal Pharmaceuticals TTM cash flow from operations is currently $312.84 million, with the most recent change of +$60.39 million (+23.92%) on 30 September 2024. Over the past year, it has increased by +$126.38 million (+67.78%). AMRX TTM CFO is now -34.57% below its all-time high of $478.10 million, reached on 31 March 2021.AMRX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AMRX Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +430.8% | +74.2% | +67.8% |
| 3 y3 years | -8.8% | +72.1% | +10.0% |
| 5 y5 years | +38.1% | +1.3% | +0.2% |
AMRX Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -8.8% | +430.8% | at high | +212.9% | -9.5% | +380.6% |
| 5 y | 5 years | -8.8% | >+9999.0% | -20.9% | +212.9% | -34.6% | >+9999.0% |
| alltime | all time | -8.8% | >+9999.0% | -45.4% | +212.9% | -34.6% | +537.2% |
Amneal Pharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $141.77 M(+257.5%) | $312.84 M(+23.9%) |
| June 2024 | - | $39.66 M(-999.3%) | $252.46 M(+25.3%) |
| Mar 2024 | - | -$4.41 M(-103.2%) | $201.46 M(-41.7%) |
| Dec 2023 | $345.58 M(+430.8%) | $135.82 M(+66.9%) | $345.58 M(+85.3%) |
| Sept 2023 | - | $81.39 M(-817.4%) | $186.46 M(-6.1%) |
| June 2023 | - | -$11.35 M(-108.1%) | $198.65 M(+135.2%) |
| Mar 2023 | - | $139.71 M(-699.8%) | $84.47 M(+29.8%) |
| Dec 2022 | $65.10 M(-73.1%) | -$23.29 M(-124.9%) | $65.10 M(-57.1%) |
| Sept 2022 | - | $93.57 M(-174.5%) | $151.65 M(+8.0%) |
| June 2022 | - | -$125.52 M(-204.3%) | $140.45 M(-34.4%) |
| Mar 2022 | - | $120.34 M(+90.2%) | $214.03 M(-11.5%) |
| Dec 2021 | $241.82 M | $63.26 M(-23.2%) | $241.82 M(-15.0%) |
| Sept 2021 | - | $82.36 M(-258.6%) | $284.52 M(+15.2%) |
| June 2021 | - | -$51.93 M(-135.1%) | $246.93 M(-48.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2021 | - | $148.13 M(+39.8%) | $478.10 M(+26.1%) |
| Dec 2020 | $379.00 M(>+9900.0%) | $105.96 M(+136.6%) | $379.00 M(+70.6%) |
| Sept 2020 | - | $44.78 M(-75.0%) | $222.15 M(-30.0%) |
| June 2020 | - | $179.24 M(+265.6%) | $317.29 M(+99.4%) |
| Mar 2020 | - | $49.03 M(-196.3%) | $159.14 M(+9233.8%) |
| Dec 2019 | $1.71 M(-99.3%) | -$50.89 M(-136.4%) | $1.71 M(-99.5%) |
| Sept 2019 | - | $139.91 M(+563.3%) | $312.25 M(+33.2%) |
| June 2019 | - | $21.09 M(-119.5%) | $234.46 M(+104.3%) |
| Mar 2019 | - | -$108.41 M(-141.8%) | $114.79 M(-54.1%) |
| Dec 2018 | $250.23 M(+6.9%) | $259.65 M(+317.9%) | $250.23 M(-2756.1%) |
| Sept 2018 | - | $62.13 M(-163.0%) | -$9.42 M(-86.8%) |
| June 2018 | - | -$98.58 M(-464.7%) | -$71.55 M(-364.7%) |
| Mar 2018 | - | $27.03 M | $27.03 M |
| Dec 2017 | $234.19 M(+103.5%) | - | - |
| Dec 2016 | $115.06 M | - | - |
FAQ
- What is Amneal Pharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for Amneal Pharmaceuticals?
- What is Amneal Pharmaceuticals annual CFO year-on-year change?
- What is Amneal Pharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for Amneal Pharmaceuticals?
- What is Amneal Pharmaceuticals quarterly CFO year-on-year change?
- What is Amneal Pharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for Amneal Pharmaceuticals?
- What is Amneal Pharmaceuticals TTM CFO year-on-year change?
What is Amneal Pharmaceuticals annual cash flow from operations?
The current annual CFO of AMRX is $345.58 M
What is the all time high annual CFO for Amneal Pharmaceuticals?
Amneal Pharmaceuticals all-time high annual cash flow from operations is $379.00 M
What is Amneal Pharmaceuticals annual CFO year-on-year change?
Over the past year, AMRX annual cash flow from operations has changed by +$280.48 M (+430.84%)
What is Amneal Pharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of AMRX is $141.77 M
What is the all time high quarterly CFO for Amneal Pharmaceuticals?
Amneal Pharmaceuticals all-time high quarterly cash flow from operations is $259.65 M
What is Amneal Pharmaceuticals quarterly CFO year-on-year change?
Over the past year, AMRX quarterly cash flow from operations has changed by +$60.39 M (+74.20%)
What is Amneal Pharmaceuticals TTM cash flow from operations?
The current TTM CFO of AMRX is $312.84 M
What is the all time high TTM CFO for Amneal Pharmaceuticals?
Amneal Pharmaceuticals all-time high TTM cash flow from operations is $478.10 M
What is Amneal Pharmaceuticals TTM CFO year-on-year change?
Over the past year, AMRX TTM cash flow from operations has changed by +$126.38 M (+67.78%)